U.S. FDA authorizes Pfizer’s COVID-19 booster for 12- to 15-year-olds

January 4th, 20220 WASHINGTON, D.C. — On Monday, the U.S. Food and Drug Administration (FDA)  authorized the use of a third dose of the Pfizer and BioNTech COVID-19 vaccine for children ages 12 to 15, and narrowed the interval for booster shot eligibility to five months from six. The agency also authorized a third shot for children aged 5- through...

FDA scientists say Pfizer vaccine is “highly effective” as outside panel meets Thursday

December 8th, 20200 U.S. Federal Food and Drug Administration (FDA) scientists have endorsed the Pfizer and BioNTech COVID-19 vaccine ahead of a committee meeting of outside experts and the FDA's eventual use authorization, the health sciences publication STAT reports. Specifically, reviewers have said the two-dose vaccine is shown to be “highly...

U.S. pauses Eli Lilly trial of antibody drug Trump touted as COVID-19 ‘cure’ over safety concern

October 14th, 20200 (REUTERS) — Eli Lilly and Co. said on Tuesday that the government-sponsored clinical trial of its COVID-19 antibody treatment similar to one taken by President Trump has been paused by the U.S. government because of a safety concern. Trump touted the Lilly drug, along with the antibody treatment from Regeneron Pharmaceuticals Inc....